capsule (extemporaneous compounding). 6, 7 Recommended dosages are shown in Table 1 .
For seasonal influenza, oseltamivir is indicated for children ≥1 year old and adults of all ages, and dosing recommendations for infants <1 year old infected with pandemic influenza are also provided. 6 Oseltamivir is an inactive prodrug:
its clinically active metabolite is oseltamivir WHO advice is to consider using the drug at higher doses and/or longer treatment duration, depending on clinical response; 9 however, UK national guidelines recommend zanamivir. 10 For treatment of influenza caused by viruses known to be resistant to oseltamivir, WHO recommends zanamivir. 9 Earlier WHO guidelines also recommend oseltamivir as the primary antiviral agent for treatment of confirmed and suspected cases of avian H5N1 influenza infection in humans; treatment should begin as soon as possible, but can be beneficial even in patients who present later in the disease course. 11, 12 Again, consideration should be given to higher doses and/or longer treatment duration, depending on the clinical course of disease. 
PHARMACODYNAMICS AND PHARMACOKINETICS

Pharmacodynamics
As already described, oseltamivir prevents the release of progeny virions from cells infected by influenza viruses, through inhibition of viral neuraminidase by its active metabolite, OC.
In humans, the standard oseltamivir dosing regimen produces a mean minimum plasma concentration of the carboxylate metabolite of approximately 330 nmol/L. 13 The majority of virus isolates from all influenza A and B subtypes tested thus far are susceptible, including seasonal, avian, and pandemic (H1N1) 2009 viruses.
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Pharmacokinetics
Oseltamivir and OC
Many of the key pharmacokinetic characteristics of oseltamivir and OC in humans were reported in the 1999 article by He and colleagues. 13 More recently, a better understanding of the pharmacokinetics in special populations has been gained. 
Special Patient Populations
The pharmacokinetics of oseltamivir after oral administration have been studied in young, healthy adults and children, as well as in elderly and very elderly subjects. [19] [20] [21] There are no clinically relevant differences between pharmacokinetics in healthy volunteers and individuals with influenza. 13 The main difference between children >1 year of age and adults in oseltamivir pharmacokinetics is that children aged 1-12 years clear the active metabolite more rapidly than adults, resulting in a lower drug exposure for a given dose; however, the exposureto-dose ratio in older children (adolescents) aged 13-18 years is similar to that in adults. 21 The higher clearance rate prompted the introduction of an age-and weight-based unit dosing system for children, to ensure comparable exposures to those in adults and to enable drug exposure in children to be maintained within a target efficacy/safety window. 
EFFICACY
Seasonal Influenza
Adults
The inhibition of influenza virus replication by Table 2 . In 167 of 179 (93.3%) Twelve contacts developed influenza, giving an estimated SAR of 5.9% (95% CI, 2.7-9.1) for all contacts; however, the SAR for the group who did not receive oseltamivir prophylaxis was 8.5%
(12/141 contacts), and for contacts who did receive prophylaxis was 0% (0/64; 95% CI, 0-0.9).
The authors gave no details on either the dosage of oseltamivir or its tolerability. 97 
RESISTANCE
Implications and Mechanism
OC binds to the influenza neuraminidase active site and inhibits neuraminidase enzyme activity or B viruses. 109 The switch in prevalence in the US over the same two seasons, however, was Table 4 . for heart rate (QTc) was observed during the treatment course. 134 In the second report, two women treated with oseltamivir for suspected pandemic (H1N1) 2009 influenza developed bradycardia. 135 The results of a retrospective cohort study, however, suggest that the risk of recurrent adverse cardiovascular outcomes such as heart failure and sudden cardiac death in patients with existing cardiovascular disease is lower in those treated with oseltamivir than those not treated, 136 and a similar benefit has been shown with respect to stroke and transient ischemic attacks. 137 An expert review of data from preclinical and clinical studies, 
Safety in Special Populations
Children
Safety data on children aged 1-12 years with seasonal influenza have demonstrated that oseltamivir is well tolerated with a similar AE profile to placebo (Table 6 ). In a pooled analysis of four treatment studies in 1032 children given the 2 mg/kg dose twice daily for 5 days, the only events that occurred more frequently in the oseltamivir group were vomiting (15% vs. 9%), abdominal pain (5% vs. 4%), and ear disorders (2% vs. 1%), with the gastrointestinal events usually occurring at the start of treatment and resolving rapidly. 144 Gastrointestinal symptoms were also the most commonly reported events in two prophylaxis studies, where treatment duration was either 10 days or 6 weeks, and the AEs seen were generally mild to moderate in intensity. 43, 145 In 146 The data reviewed by CHMP included interim pharmacokinetic and safety data from the prospective study, CASG114, (US National Institutes of Health; ClinicalTrials. Table 6 . Adverse drug reactions reported in ≥1% of patients in the oseltamivir group in studies investigating oseltamivir for the treatment or prevention of influenza in children and in post-marketing surveillance (pooled analysis). 
Elderly Patients
The pooled analysis of oseltamivir treatment studies mentioned above also included a comparison of AE incidence between elderly adults aged ≥65 years and adults <65 years old; the only differences were that elderly treated patients reported a lower incidence of nausea and vomiting and a higher incidence of dyspepsia. 144 The safety of oseltamivir was also 
